NEW YORK – Biopharmaceutical company Precigen has begun enrolling patients in a Phase I/II clinical trial to explore the activity of its immunotherapy PRGN-2009 alone and in combination with bintrafusp alfa, Merck KGaA and GlaxoSmithKline's investigational bifunctional fusion protein immunotherapy, in human papillomavirus-positive solid tumors.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.